Overview

The drug candidate REDECTANE®* is based on an antibody and is being developed for the pre-surgical diagnosis of clear cell Renal Cell Cancer. REDECTANE® is the radioactively labelled form of the antibody WX-G250. The labelled antibody WX-G250 targets clear cell renal cell carcinoma and accumulates in the tumour tissue. This accumulation can be visualised by means of Positron Emission Tomography (PET).

The Cooperation partner of WILEX, the Ludwig Institute for Cancer Research, New York carried out a proof-of-concept trial in cooperation with the Memorial Sloane-Kettering Cancer Center, New York. This feasibility study found that a positive result with REDECTANE® was confirmed as clear cell renal cell carcinoma in 100% of cases (positive predictive value).

REDECTANE® could determine whether the patient had clear cell renal cell carcinoma before surgery and the subsequent pathology. Therefore, REDECTANE® could significantly improve and simplify treatment planning for patients suspected of having renal cancer. The company is not aware of any other available imaging technique with comparable specificity and sensitivity.

* temporary name while under development